Table 4.
Patient characteristics of the training and validating datasets.
| Characteristics | Training dataset | Validating dataset | P value$ |
|---|---|---|---|
| Sample size | 258 | 233 | |
| Age, year mean (SD) | 59.8 (11.2) | 60.34 (9.9) | 0.59 |
| Histologic grade (%) | 6.61 × 10−12 | ||
| 2 | 35 (13.6) | 80 (34.3) | |
| 3 | 223 (86.4) | 138 (59.2) | |
| 4 | 0 | 15 (6.4) | |
| Stage #(%) | 0.10 | ||
| II | 14 (5.4) | 14 (6.0) | |
| III | 206 (79.8) | 199 (85.4) | |
| IV | 38 (14.7) | 20 (8.6) | |
| Platinum sensitivity (%) | 0.02 | ||
| Sensitive | 190 (68.1) | 185 (79.3) | |
| Response to therapy& | — | ||
| CR | 194 (69.5) | 0 | |
| Non-CR | 63 (22.6) | 0 | |
| Unknown | 22 (7.9) | 233 (100) | |
| Molecular subtypes | 0.47 | ||
| Proliferative | 77 (29.8) | 71 (30.5) | |
| Mesenchymal | 51 (19.7) | 39 (16.7) | |
| Immunoreactive | 62 (24.0) | 69 (29.6) | |
| Differentiated | 68 (26.3) | 54 (23.2) |
#Stage based on the International Federation of Gynecology & Obstetrics (FIGO).
&CR means the complete response, and Non-CR depicts a non-complete response, including partial response, progressive disease, and stable disease.
$p values for the difference between the derivation and validation cohorts were calculated using independent sample t-test (for age and height) and Chi square test (for histologic grade, stage, platinum sensitivity, response to therapy, and molecular subtypes).